PrometheraÂ® Biosciences is a biopharmaceutical company, spin-off of the UniversitÃ© Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.
PrometheraÂ® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
PrometheraÂ® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):
Funding Rounds (2) - $38.8MUpdate
Mitsui Global Investment (MGI) is a subsidiary of Mitsui & Co., Ltd., which invests in...
Shire PLC is a specialty biopharmaceutical company.
Venture Capital Firm
LSP (Life Sciences Partners) is a leading independent European investment firm, providing...
The S.R.I.W. and its subsidiaries together form the S.R.I.W. Group, whose mission is to intervene...
Vesalius Biocapital Partners manages a mid-size venture capital fund that invets in young, early...
Watson & Crick Hill
Rue GranbonprÃ©, 11